Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus. Issue 11 (4th October 2021)

• Record Type: Journal Article
• Authors: Mandl, Adel; Welch, James M; Kapoor, Gayathri; Parekh, Vaishali I; Schrump, David S; Ripley, R Taylor; Walter, Mary F; Del Rivero, Jaydira; Jha, Smita; Simonds, William F; Jensen, Robert T; Weinstein, Lee S; Blau, Jenny E; Agarwal, Sunita K
• Is Part Of: Endocrine-related cancer. Volume 28:Issue 11(2021)
• Page Start: L15
• Page End: L19
• Publication Date: 2021-10-04
• Subjects: multiple endocrine neoplasia -- neuroendocrine tumor -- thymic carcinoid -- thymoma -- thymus; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-21-0226
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : Patients with the multiple endocrine neoplasia type 1 (MEN1) syndrome carry germline heterozygous loss-of-function mutations in the MEN1 gene which predisposes them to develop various endocrine and non-endocrine tumors. Over 90% of the tumors show loss of heterozygosity (LOH) at chromosome 11q13, the MEN1 locus, due to somatic loss of the wild-type MEN1 allele. Thymic neuroendocrine tumors (NETs) or thymic carcinoids are uncommon in MEN1 patients but are a major cause of mortality. LOH at the MEN1 locus has not been demonstrated in thymic tumors. The goal of this study was to investigate the molecular aspects of MEN1-associated thymic tumors including LOH at the MEN1 locus and RNA-sequencing (RNA-Seq) to identify genes associated with tumor development and potential targeted therapy. A retrospective chart review of 294 patients with MEN1 germline mutations identified 14 patients (4.8%) with thymic tumors (12 thymic NETs and 2 thymomas). LOH at the MEN1 locus was identified in 10 tumors including the 2 thymomas, demonstrating that somatic LOH at the MEN1 locus is also the mechanism for thymic tumor development. Unsupervised principal component analysis and hierarchical clustering of RNA-Seq data showed that thymic NETs formed a homogenous transcriptomic group separate from thymoma and normal thymus. KSR2 (kinase suppressor of Ras 2), that promotes Ras-mediated signaling, was abundantly expressed in thymic NETs, a potential therapeutic target. The molecular insights gained from our study about thymic tumors combined with similar data from other MEN1-associated tumors may lead to better surveillance and treatment of these rare tumors.